Save the Date: Egetis to host Investor Day on December 18, 2024

Stockholm, Sweden, November 25, 2024. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced that the Company will host an Investor Day on Wednesday, December 18, 2024, in Stockholm, Sweden, for investors and analysts.

Time: Wednesday, December 18, 2024, at 15:00 - 18:00 CET (9:00 am – 12:00 pm ET)
Venue: Redeye, Mäster Samuelsgatan 42, Stockholm, Sweden

The event will also be accessible through a live webcast.

During the event, the Company will provide an update and review of its strategy and pipeline. The presentations will focus on the unmet medical need, development plans, pre-launch activities and commercialization plans for the investigational drug tiratricol (Emcitate®), being developed as a possible treatment for MCT8 deficiency, as well as additional activities to create and enhance long-term shareholder value. Presentations will be made by members of Egetis’ management team and invited key opinion leaders.

A complete agenda and a link to the live webcast will be shared in advance of the event.
Presentations will be held in English.

If you would like to attend the event in person in Stockholm, please register by email to info@egetis.com

Datum 2024-11-25, kl 14:15
Källa MFN
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet